These novel medications , Tirzepatide , represent a significant advancement in addressing obesity and potentially associated disorders. They all are grouped as GLP-1 pathway agonists , signifying they https://marcocto671235.csublogs.com/49285085/semaglutide-a-thorough-dive-into-glp-1-compounds